Brimarafenib

N/A

Report date: 2025/06/16 16:57:36
NME

Base Information

Drug NameBrimarafenib
Drug Alias NameBGB-3245BGB-3245-MBPBGB-245
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitors
TargetsSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeOne Medicines (Beijing) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeOne Medicines (Beijing) Co Ltd
Inactive CompaniesMapkure LlcSpringworks Therapeutics Inc
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Inactive IndicationsCarcinoma, Pancreatic DuctalNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A